ATP11A and ATP11C are plasma membrane phosphatidylserine flippases in in vitro human megakaryocytes
Preprint
Abstract
Thrombotic diseases are the major worldwide cause of cardiovascular death. Platelets prevent blood loss following injury (haemostasis), but inappropriate and excessive platelet activation can lead to thrombosis. Platelet activation must be tightly controlled. Pro-coagulant platelets expose phosphatidylserine (PS), enabling coagulation complex assembly, enhancing thrombin generation and thrombosis. PS is normally restricted to the inner leaflet of the plasma membrane by ‘flippase’ (aminophospholipid translocase) activity. However, the flippase protein(s) responsible for this crucial activity in platelets remains unidentified. The P4 ATPases ATP11A and ATP11C, regulated by their obligatory partner CDC50A, flip PS at the plasma membrane in a range of different cell types. To investigate platelet flippases, human induced pluripotent stem cells (hiPSCs) were forward-programmed into CD41 + /CD42 + megakaryocytes, the platelet precursor. Wildtype (WT) forward-programmed megakaryocytes showed similar flippase activity to human platelets with internalisation of NBD-PS that could be inhibited by high cytosolic Ca 2+ or N -ethylmaleimide (NEM). We then generated CDC50A, ATP11A or ATP11C single knockout and ATP11A/11C double knockout (DKO) hiPSCs using CRISPR-Cas9. CDC50A-KO, ATP11A-KO, ATP11C-KO and DKO hiPSC clones successfully formed CD41a + /CD42a + mature megakaryocytes. CDC50A-KO megakaryocytes bound Annexin V when unstimulated and had no remaining NEM-sensitive flippase activity indicating the involvement of a P4-ATPase. Although ATP11A-KO and ATP11C-KO megakaryocytes had similar flippase activity to WT clones, DKO clones had inhibited NBD-PS internalisation compared to WT and had no remaining NEM-sensitive flippase activity. This indicates that the CDC50A-regulated P4-ATPases ATP11A and ATP11C act together at the megakaryocyte plasma membrane and are responsible for PS flippase activity and therefore likely responsible in human platelets.Keywords
Funding Information
- British Heart Foundation (PG/23/11601)
- British Heart Foundation (FS/4yPhD/F/21/34156)
- British Heart Foundation (PG/20/12/34982)
This publication has 35 references indexed in Scilit:
- A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemiaAmerican Journal of Hematology, 2023
- Postpartum haemorrhage - an insurmountable problem?Case Reports in Women's Health, 2023
- Mobilizing phospholipids on tumor plasma membrane implicates phosphatidylserine externalization blockade for cancer immunotherapyCell Reports, 2022
- Two types of type IV P-type ATPases independently re-establish the asymmetrical distribution of phosphatidylserine in plasma membranesJournal of Biological Chemistry, 2022
- TMEM16F Forms a Ca2+-Activated Cation Channel Required for Lipid Scrambling in Platelets during Blood CoagulationCell, 2012
- Activated scramblase and inhibited aminophospholipid translocase cause phosphatidylserine exposure in a distinct platelet fractionCellular and Molecular Life Sciences, 2005
- Translocation of spin-labeled phospholipids through plasma membrane during thrombin- and ionophore A23187-induced platelet activationBiochemistry, 1993
- Increased aminophospholipid translocase activity in human platelets during secretionBiochimica et Biophysica Acta (BBA) - Biomembranes, 1990
- Purification and properties of a vanadate- and N-ethylmaleimide-sensitive ATPase from chromaffin granule membranes.Journal of Biological Chemistry, 1988
- Selective outside-inside translocation of aminophospholipids in human plateletsBiochemistry, 1987